



EU BIOTECH DAYS at BIOTECHNICA 2008

“Building the Future of Pioneering Technologies in Europe”



European Parliament Panel Discussion with Representatives from the Industry
on 7 October 2008 in Hannover/Germany (Convention Center/Room 1B)

Area	Time	Topic	Member of the European Parliament	Member of the Industry	Moderation/Chair
Green	10.30-11.30	<p><u>Globalization and uniform markets:</u></p> <p>Why does it take so much longer to get new plants approved in Europe than in the U.S., and why can GMO (genetically modified organisms) plants that have been approved for consumption in non-European countries be imported in the EU, while the very same plants cannot be cultivated within the EU?</p>	<p>Erika Mann (Socialist Group) (conf.) Member in the Committee on International Trade (INTA) and on the Delegation for Relations with the United States (D-US), Substitute in the Committees on Industry, Research and Energy (ITRE) and Budgetary Control (CONT)</p>	<p>Dr. Léon Broers (conf.) Member of the Board of KWS Saat AG, D-Einbeck</p>	<p>Dr. Jens A. Katzek (conf.) Managing Director of BIO Mitteldeutschland GmbH, D-Halle</p>
Green/White	11.30-12.30	<p><u>EU climate targets:</u></p> <p>Why is the immense potential that biotechnology and gene technology offer for achieving EU climate targets not being used?</p>	<p>Rebecca Harms (Group of the Greens) (conf.) Vice-Chairwoman in the Committee on Climate Change (CLIM), Member in the Committee on Industry, Research and Energy (ITRE), Substitute in the Committee on the Environment, Public Health and Food Safety (ENVI)</p>	<p>Thomas Gameson (conf.) Government and Public Affairs Manager of Abengoa Bioenergy S.A., E-Sevilla</p>	<p>Dr. Dirk Carrez (conf.) Director Public Policy and Industrial Biotech of The European Associations for Bioindustries (EuropaBio), B-Brussels</p>
Meetings in the Exhibition Hall					
Business	14.00-15.00	<p><u>Europe's fragmented stock markets:</u></p> <p>The lack of a strong, standardized marketplace for shares in young biotechnology companies puts Europe at a clear disadvantage compared to other growth regions. Why is this accepted?</p>	<p>Dr. Christian Ehler (Christian Democrats Group) (tbc.) Member in the Committee on Economic and Monetary Affairs (ECON), Substitute in the Committee on Industry, Research and Energy (ITRE)</p>	<p>Prof. Dr. Olaf G. Wilhelm (conf.) Chief Executive Officer and Chairman of the Executive Management Board of WILEX AG, D-München</p>	<p>Christoph Hardt (conf.) Editor of the Companies & Markets Section of HANDELSBLATT, D-Düsseldorf</p>
Red	15.00-16.00	<p><u>Adult stem cells:</u></p> <p>The advantages of adult stem cells and which hurdles are there in Europe?</p>	<p>Dr. Alojz Peterle (Christian Democrats Group) (conf.) Member in the Committee on Foreign Affairs (AFET) and on the Subcommittee on Human Rights (DROI), Substitute in the Committee on the Environment, Public Health and Food Safety (ENVI)</p>	<p>Dr. Nico Forraz (conf.) Head of Scientific Dpt of Cryo-Save Group NV, NL-Zutphen</p>	<p>Prof. Dr. Detlev Ganten (conf.) Chairman of the Executive Board of Charité, D-Berlin</p>